K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 6.04 CAD 0.33%
Market Cap: 601.8m CAD

Relative Value

The Relative Value of one GUD stock under the Base Case scenario is 5.05 CAD. Compared to the current market price of 6.04 CAD, Knight Therapeutics Inc is Overvalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GUD Relative Value
Base Case
5.05 CAD
Overvaluation 16%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
80
vs Industry
58
Median 3Y
1.7
Median 5Y
2.2
Industry
2.5
Forward
1.5
vs History
15
vs Industry
2
Median 3Y
-27.1
Median 5Y
-18.5
Industry
21.5
Forward
106.2
vs History
3
vs Industry
26
Median 3Y
15.4
Median 5Y
15
Industry
16.6
vs History
vs Industry
19
Median 3Y
16.1
Median 5Y
-3.2
Industry
24.9
vs History
39
vs Industry
67
Median 3Y
0.7
Median 5Y
0.7
Industry
2.1
vs History
79
vs Industry
66
Median 3Y
1.3
Median 5Y
1.4
Industry
2.7
Forward
1.2
vs History
73
vs Industry
63
Median 3Y
2.9
Median 5Y
3.2
Industry
5.2
vs History
60
vs Industry
38
Median 3Y
8.7
Median 5Y
9.7
Industry
12.8
Forward
9.1
vs History
vs Industry
6
Median 3Y
-32.4
Median 5Y
-27
Industry
16.3
Forward
23.2
vs History
3
vs Industry
33
Median 3Y
11.6
Median 5Y
11
Industry
14.9
vs History
vs Industry
5
Median 3Y
21.1
Median 5Y
8.8
Industry
17.9
vs History
14
vs Industry
69
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

GUD Competitors Multiples
Knight Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Knight Therapeutics Inc
TSX:GUD
600.7m CAD 1.6 54.3 9.2 -588
US
Eli Lilly and Co
NYSE:LLY
775.7B USD 15.8 70 37.4 40.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.6B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.3
CH
Roche Holding AG
SIX:ROG
215B CHF 3.6 26 9.7 11.4
CH
Novartis AG
SIX:NOVN
190.4B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
168.9B GBP 4.2 29.4 131.2 197.9
US
Merck & Co Inc
NYSE:MRK
203.8B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 17.8 7.6 10.7
P/E Multiple
Earnings Growth PEG
CA
K
Knight Therapeutics Inc
TSX:GUD
Average P/E: 29.6
54.3
23%
2.4
US
Eli Lilly and Co
NYSE:LLY
70
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
26
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBITDA: 395.4
9.2
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBIT: 1 867.7
Negative Multiple: -588
20%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.9
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1